Posted by Michael Wonder on 06 Jun 2026
Xspray Pharma receives CRL from US FDA for Nilopki
4 June 2026 - Xspray Pharma has received a complete response letter from the US FDA for its new drug application for Nilopki, an optimised formulation of nilotinib.
The company will address remaining questions with FDA; long‑term strategy and HyNap platform remain unchanged.
